Major depressive disorder (MDD)
Conditions
Brief summary
During the study, participants will record the answers given to a questionnaire designed to measure emotional experiences, called Oxford Depression Questionnaire (ODQ). The outcome will be measured by the changes in the score recorded at the beginning of patients’ participation compared to the one after 8 weeks of treatment.
Detailed description
Other parameters evaluated will be the evolution of depression and the effect on cognition, sleep, and overall quality of life. The effect of the treatment on functioning at work or school, in social situations, or with family and home responsibilities will be also assessed using scales and questionnaires designed for these purposes.
Interventions
Sponsors
Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| During the study, participants will record the answers given to a questionnaire designed to measure emotional experiences, called Oxford Depression Questionnaire (ODQ). The outcome will be measured by the changes in the score recorded at the beginning of patients’ participation compared to the one after 8 weeks of treatment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Other parameters evaluated will be the evolution of depression and the effect on cognition, sleep, and overall quality of life. The effect of the treatment on functioning at work or school, in social situations, or with family and home responsibilities will be also assessed using scales and questionnaires designed for these purposes. | — |
Outcome results
None listed